Publications
130 results found
Murray A, Cass L, Ito K, et al., 2020, PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections, JOURNAL OF FUNGI, Vol: 6
- Author Web Link
- Cite
- Citations: 13
Williams TJ, Harvey S, Armstrong-James D, 2020, Immunotherapeutic approaches for fungal infections, CURRENT OPINION IN MICROBIOLOGY, Vol: 58, Pages: 130-137, ISSN: 1369-5274
- Author Web Link
- Cite
- Citations: 10
Pagani N, Armstrong-James D, Reed A, 2020, Successful salvage therapy for fungal bronchial anastomotic infection after-lung transplantation with an inhaled triazole anti-fungal PC945, JOURNAL OF HEART AND LUNG TRANSPLANTATION, Vol: 39, Pages: 1505-1506, ISSN: 1053-2498
- Author Web Link
- Cite
- Citations: 8
Nuh A, Ramadan N, Schelenz S, et al., 2020, Comparative Evaluation of MIRONAUT-AM and CLSI broth microdilution method for antifungal susceptibility testing of <i>Aspergillus species</i> against four commonly used antifungals, MEDICAL MYCOLOGY, Vol: 58, Pages: 1085-1090, ISSN: 1369-3786
- Author Web Link
- Cite
- Citations: 7
Armstrong-James D, Youngs J, Bicanic T, et al., 2020, Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA), European Respiratory Journal, Vol: 56, Pages: 1-10, ISSN: 0903-1936
Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections.The SARS-CoV-2 (COVID-19) virus causes a wide spectrum of disease in healthy individuals as well as those with common comorbidities [1]. Severe COVID-19 is characterised acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis, treatment of which may require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) [2]. Clinicians are alert to the possibility of bacterial co-infection as a complication of lower respiratory tract viral infection; for example a recent review found that 72% of patients with COVID-19 received antimicrobial therapy [3]. However, the risk of fungal co-infection, in particular COVID-19 associated pulmonary aspergillosis (CAPA), remains underappreciated.Fungal disease consistent with invasive aspergillosis (IA) has been observed with other severe Coronaviruses such as Severe Acute Respiratory Syndrome (SARS-CoV-2003) [4, 5] and Middle East Respiratory Syndrome (MERS-CoV) [6]. From the outset of the COVID-19 pandemic, there were warning signs of secondary invasive fungal infection; Aspergillus flavus was isolated from the respiratory tract from one of 99 patients in the first COVID-19 cohort from Wuhan to be reported in any detail [2] and Aspergillus spp. were isolated from 2/52 (3.8%) of a subsequent cohort of critically unwell patients from this region [7]. More recently, retrospective case series from Belgium [8], France [9], The Netherlands [10] and Germany [11] have reported evidence of CAPA in an alarming 20–35% of mechanically ventilated patients.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.